Prescribing Information

ALECENSA^®▼(alectinib)

Avastin^® (bevacizumab)

Esbriet^® (pirfenidone)

GAZYVARO^® (obinutuzumab)

HEMLIBRA^®▼(emicizumab)

Herceptin^® (trastuzumab) IV

Herceptin^® (trastuzumab) SC

Kadcyla^®(trastuzumab emtansine)

OCREVUS^®▼(ocrelizumab)

Perjeta^® (pertuzumab)

PHESGO^®▼ (pertuzumab/trastuzumab)

Polivy^®▼ (polatuzumab vedotin)

RoACTEMRA^®(tocilizumab) RA/GCA

RoACTEMRA^® (tocilizumab) pJIA/sJIA

RoACTEMRA^® (tocilizumab) CRS

Rozlytrek^®▼(entrectinib)

Tecentriq^®▼(atezolizumab) HCC

Tecentriq^®▼(atezolizumab) Lung Cancer

Tecentriq^®▼(atezolizumab) mTNBC

Tecentriq^®▼(atezolizumab) mUC

IV, intravenous; SC, subcutaneous; GPA, granulomatosis with polyangiitis; MPA, microscopic polyangiitis; RA, rheumatoid arthritis; GCA, giant cell arteritis;  HCC  Hepatocellular carcinoma; pJIA, polyarticular juvenile idiopathic arthritis; sJIA, systemic juvenile idiopathic arthritis; NSCLC, Non-small-cell lung carcinoma; UC, urothelial carcinoma; mTNBC, metastatic triple-negative breast cancer

For the Summary of Product Characteristics for all Roche products available in the UK please see www.medicines.org.uk/emc.

M-GB-00002435

Date of preparation: January 2021